Ohio Medicaid and GLP-1 coverage

Ohio's pharmacy rule names obesity drugs as non-covered, in a list: "Drugs that fall into one of the following categories are non-covered by the Ohio medicaid pharmacy program: (1) Drugs for the treatment of obesity." The same rule then closes the usual escape hatch. Under prior authorization it says that "noncovered drugs listed in paragraphs (B)(1) to (B)(5) of this rule and APIs and excipients not on the list described in paragraph (A)(3) of this rule are not eligible for prior authorization." So for a weight-loss indication there is no criteria document to satisfy and no exception to file.

Ohio Administrative Code, Rule 5160-9-03, Ohio Laws and Administrative Rules, effective February 2024 · source

Wegovy is on Ohio's statewide list as of April 1, 2026, under the class heading "GLP-1 AGONISTS FOR NON-OBESITY INDICATIONS," with authorizations running 180 days. There are two approvable diagnoses. One is major adverse cardiovascular events, requiring "Age ≥18 years" and "BMI ≥27 kg/m 2" plus documented prior myocardial infarction, prior stroke or symptomatic peripheral artery disease. The other is noncirrhotic MASH with stage F2 or F3 liver fibrosis. The list adds that "WEGOVY will not be authorized for patients with type 1 or type 2 diabetes."

Ohio Medicaid Pharmacy Benefit Management Program, Unified Preferred Drug List, effective April 2026 · source

Weight loss is a monitoring test on that authorization, not a way in. To keep Wegovy going, the criteria require that "Documentation (chart notes) must be submitted to show weight loss from baseline greater than or equal to 5%." You have to lose weight to stay on it, and you cannot get on it for losing weight. Both of those come from the same document.

Ohio Medicaid Pharmacy Benefit Management Program, Unified Preferred Drug List, effective April 2026 · source

Ohio's October 1, 2025 list is our control for the paragraph above, and it is worth citing on its own. Searching it for Wegovy returns nothing, and the non-obesity GLP-1 class does not appear in it at all, while the same file carries the same diabetes GLP-1 roster the April list carries. The search works on the older document, so Wegovy's arrival in April 2026 is a change Ohio made, not a difference in how we read the two files.

Ohio Medicaid Pharmacy Benefit Management Program, Unified Preferred Drug List, effective October 2025 · source

Shopping between Ohio Medicaid plans will not get you a different answer, because they all use the same drug list and the same pharmacy administrator. State law directs that "the medicaid director, through a procurement process, shall select a third-party administrator to serve as the single pharmacy benefit manager used by medicaid managed care organizations under the care management system." The list itself is titled for "Medicaid Fee-for-Service and Managed Care Plans."

Ohio Revised Code §5167.24, Ohio Laws and Administrative Rules, effective September 2025 · source · Unified PDL

If an Ohio managed care plan or the state pharmacy benefit manager denies you, there are two clocks and you have to run them in order. First the plan's own appeal: a member or representative "may file an appeal orally or in writing within sixty calendar days from the date that the NOA was issued." You cannot skip it — "members may request a state hearing only after exhausting the MCO or SPBM's appeal process." Then the hearing: you "may request a state hearing within ninety calendar days from the date of an adverse appeal resolution." This rule is written for managed care members; we did not reach Ohio's fee-for-service hearing deadline, so we are not stating one.

Ohio Administrative Code, Rule 5160-26-08.4, Ohio Laws and Administrative Rules, effective January 2023 · source